Friday 6 November 2026
Export AUPH’s income statement to Excel — free account
Aurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
16.40
0.19
+1.17%
Follow AUPH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 7 | 7 | 7 |
| 59.91% | 64.98% | 66.12% | 61.42% | ||
| 44.11% | 48.54% | 48.52% | 46.45% | ||
ROIC |
30.35% | 34.24% | 40.76% | 42.95% | |
Return on Tangible Assets |
71.74% | 75.37% | 70.86% | 63.67% | |
Average Days of Receivables |
53.46 | 60.17 | 48.20 | 53.79 | |
Free Cash Flow per Share |
1.01 | 1.26 | 1.35 | 1.33 | |
Free Cash Flow |
135.41 | 166.64 | 175.07 | 177.03 | |
Capital Expenditures |
(0.25) | (0.27) | (0.18) | (0.13) | |
| Other line items | |||||
Cash ROIC |
13.13% | 16.76% | 15.89% | 14.96% | |
Accounts Receivable Turnover |
7.26 | 6.66 | 7.67 | 8.23 | |
Accounts Payable Turnover |
7.69 | 8.89 | 11.90 | 11.54 | |
Inventory Turnover |
0.77 | 0.66 | 0.66 | 0.68 | |
Average Days of Payables |
37.02 | 31.74 | 21.08 | 36.47 | |
Days of Inventory on Hand |
510.54 | 553.66 | 548.68 | 529.11 | |
Tax Rate |
1.52 | 1.23 | 0.96 | 0.88 | |
Research and Development Expense of Revenue |
11.48% | 11.48% | 12.79% | 14.93% | |
Selling, General and Administrative Expense of Revenue |
35.96% | 34.69% | 32.41% | 30.92% | |
Share Based Compensation of Revenue |
5.19% | 5.77% | 4.69% | 4.61% | |
Interest Coverage |
26.43 | 30.38 | 34.25 | 37.19 | |
Operating CF/Net income |
0.47 | 0.56 | 0.56 | 0.56 | |
Depreciation/Fixed assets |
9.21 | 9.77 | 10.41 | 11.14 | |
Capex/Depreciation |
(0.01) | (0.01) | (0.01) | (0.01) | |
Revenue per Share |
2.11 | 2.25 | 2.39 | 2.41 | |
Operating CF per Share |
1.01 | 1.26 | 1.35 | 1.33 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026